Percheron raises $2.2 million to back phase II push for HMBD-002

Percheron Therapeutics Ltd (ASX:PER, OTC:PERCF) has secured $2.2 million through a fully subscribed entitlement offer, ...

Anixa Biosciences Highlights Lean Cash Burn, CAR-T Survival Signals, and Phase II Vaccine Plan at Conference

CEO Dr. Amit Kumar outlined the company’s strategy for advancing two clinical-stage oncology programs while maintaining what ...
Fierce Biotech

Alto halts work on PDE4 inhibitor after phase 2 schizophrenia failure

Alto Neurosciences is halting work on its schizophrenia prospect after the brain-penetrant drug flunked a phase 2 study. The Bay Area biotech evaluated 10 days of treatment with t ...
Clinical Trials Arena on MSN

IDEAYA reports top line data from Phase II/III trial of darovasertib combo

The trial enrolled 210 patients in the darovasertib combination arm and 103 in the ICT arm.

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ...
ascopubs.org

Randomized phase II study to evaluate treatment with induction therapy with nivolumab plus ipilimumab, followed by nivolumab with chemoradiotherapy versus standard of care with ...

TroFuse-020/GOG-3101/ENGOT-cx20: A phase 3, randomized, active-controlled, open-label, multicenter study comparing sacituzumab tirumotecan monotherapy vs treatment of ...
The Aviationist

Northrop Grumman Advances to Phase II of U.S. Army Aviation New Threat Detection System

ITDS Phase II brings ATHENA sensor to Army aircraft, providing 360° situational awareness and enhanced survivability against evolving threats. Northrop Grumman has been selected by the U.S. Army to ...
ascopubs.org

A phase II study of ACR-368 and low dose gemcitabine combination therapy in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.

HexAgon-HN: Phase 2/3, randomized study of the hexavalent OX40 agonist INBRX-106 in combination with pembrolizumab vs pembrolizumab alone as first-line treatment for recurrent/metastatic head and neck ...